Skip to main content
Fig. 3 | Journal of Pharmaceutical Health Care and Sciences

Fig. 3

From: Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer

Fig. 3

Time to onset of respiratory failure. Time from COVID-19 diagnosis to the onset of respiratory failure. Patients were sub-grouped into (a) high and low C-reactive protein (CRP) groups based on calculated cutoff values as well as (b) groups with and without prior immune checkpoint inhibitor (ICI) administration within 90 days. Log-rank test, *p < 0.05. ICI ≤ 90 d, ICI within 90 days. ICI ≥ 91 d + non-ICI, ICI over 91 days + non-ICI

Back to article page